Post-Nephrectomy Management for T3a Grade 3 Clear Cell RCC

Risk Stratification

• The patient falls into the high-risk category based on the SSIGN scoring system, with T3a disease scoring 4 points and nuclear grade 3 scoring 1 point, resulting in a total score ≥5, which is associated with a 5-year metastasis-free survival of approximately 31.2% 1, 4
• The combination of T3a staging and grade 3 histology places the patient at substantial risk for recurrence 4

Current Standard of Care: Observation

• The established guidelines clearly state there is no recommended adjuvant treatment following nephrectomy for localized or locally advanced RCC, as no adjuvant therapy has demonstrated overall survival benefit 1, 2, 3, 4
• Active surveillance with regular imaging is the primary approach for an elderly patient with T3a grade 3 clear cell RCC, as it remains the guideline-recommended standard of care 1, 2, 3, 4

Adjuvant Therapy Considerations

• Pembrolizumab may be considered for high-risk patients, given its recent overall survival benefit, although its use in this patient's scenario (T3a post-nephrectomy without metastasectomy) may not derive the same magnitude of benefit 5
• Sunitinib is not recommended for elderly patients due to its high toxicity rate without overall survival benefit 4

Recommended Management Algorithm

• The patient should undergo active surveillance with regular imaging, including CT imaging of chest, abdomen, and pelvis, to detect recurrence early 2, 4
• Clinical trial enrollment should be considered if available, as guidelines strongly encourage trial participation for high-risk patients 1, 2, 4

Special Considerations for Elderly Patients

• Elderly patients have increased vulnerability to treatment-related toxicity, and quality of life considerations become paramount when survival benefit is uncertain 3
• Active surveillance may be preferable to aggressive adjuvant therapy in this population, given the uncertain survival benefit and potential toxicity 3

Surveillance Strategy

• Regular follow-up imaging should be implemented to detect recurrence early, allowing for prompt initiation of systemic therapy when metastatic disease develops 2, 4
• Modern targeted therapies and immunotherapies have dramatically improved outcomes for metastatic disease, with a median survival now ~30 months vs ~15 months historically 5